Latin American Pharmaceutical Market Set To Grow To $126bn By 2022

08 August 2018
Pharma

Visiongain has launched a new pharma report Latin American Pharmaceutical Market Outlook 2018-2028: Brazil, Mexico, Venezuela, Argentina, Colombia, Chile, Rest of Latin America, Generics, OTC, Biosimilars, Originator Drugs

The Latin American pharmaceutical market accounts for 8% of the global pharmaceutical industry, and is one of its fastest growing markets. Macroeconomic conditions are hampering growth in the short term, but long-term growth is expected at high rates to 2028 and beyond. Many multinational companies have successfully gained entry to this market and are making large gains, but it remains a challenging environment for new entrants. The Latin American market requires strong local knowledge, as there are large differences between its constituent nations.

The lead analyst of this report said “The Latin American pharmaceutical market will continue to grow at a much higher rate than other, more mature markets for the next ten years. The reasons behind this growth will shift from expanding coverage to increasing incidence of diseases as the nations of Latin America develop economically. Governments across the region are looking to increase access to health care and an ageing population coupled with rises in the incidence of chronic diseases are driving demand.

Competition is high from both foreign and domestic companies, and national regulations can make investment difficult. Nevertheless, success in the Latin American pharmaceutical market is crucial for pharmaceutical companies seeking to maintain growth rates as developed markets stagnate.”

Leading companies featured in the report include Pfizer Inc., Bayer AG, Sanofi S.A, Novartis AG
And EMS SA.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever